177 related articles for article (PubMed ID: 37552677)
21. DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C DO NOT AFFECT THE RISK OF DEVELOPMENT OR THE OUTCOME OF HEPATOCELLULAR CARCINOMA.
Gogichaishvili L; Lobjanidze G; Tsertsvadze T; Chkhartishvili N; Jangavadze M
Georgian Med News; 2020 Sep; (306):76-81. PubMed ID: 33130651
[TBL] [Abstract][Full Text] [Related]
22. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
23. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
24. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Ohnami S; Nagashima T; Hatakeyama K; Kakuda Y; Sugino T; Urakami K; Akiyama Y; Yamaguchi K
Cancer Med; 2022 Apr; 11(8):1769-1786. PubMed ID: 35174643
[TBL] [Abstract][Full Text] [Related]
25. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.
Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP
Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751
[TBL] [Abstract][Full Text] [Related]
26. Chronic Hepatitis C: Advances in Therapy and the Remaining Challenges.
Alqahtani SA; Sulkowski MS
Med Clin North Am; 2023 May; 107(3):423-433. PubMed ID: 37001945
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents.
Chen Q; Ayer T; Adee MG; Wang X; Kanwal F; Chhatwal J
JAMA Netw Open; 2020 Nov; 3(11):e2021173. PubMed ID: 33206188
[TBL] [Abstract][Full Text] [Related]
28. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
29. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
30. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
Wang CC; Tseng KC; Tzeng IS; Kao JH
J Formos Med Assoc; 2021 Mar; 120(3):965-973. PubMed ID: 33129621
[TBL] [Abstract][Full Text] [Related]
31. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
[TBL] [Abstract][Full Text] [Related]
32. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
[No Abstract] [Full Text] [Related]
34. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
35. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
[TBL] [Abstract][Full Text] [Related]
37. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection.
Martinez MA; Franco S
Adv Exp Med Biol; 2021; 1322():139-157. PubMed ID: 34258740
[TBL] [Abstract][Full Text] [Related]
38. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
Vallet-Pichard A; Correas JM; Dorival C; Zoulim F; Tran A; Bourlière M; Calès P; Guyader D; Bronowicki JP; Larrey D; Hezode C; Loustaud-Ratti V; Gournay J; de Ledinghen V; Asselah T; Ganne N; Metivier S; Chazouillères O; Leroy V; Rosa I; Samuel D; Mathurin P; Cagnot C; Fontaine H; Carrat F; Pol S;
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101459. PubMed ID: 32595103
[TBL] [Abstract][Full Text] [Related]
39. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
[TBL] [Abstract][Full Text] [Related]
40. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]